Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + ranitidine
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Chlorpheniramine + ranitidine is a combination of two small molecule drugs. Chlorpheniramine is a first-generation antihistamine that acts as a histamine H1 receptor antagonist, commonly used to manage symptoms associated with upper respiratory allergies such as rhinitis, urticaria, and hay fever[1]. Ranitidine is an H2 receptor antagonist primarily used to reduce gastric acid secretion in conditions like peptic ulcer disease and gastroesophageal reflux disease[4]. The combination has been studied for its potential additive or synergistic effects in reducing histamine-induced wheal and flare reactions, with evidence suggesting that the addition of ranitidine may enhance the antihistaminic effect of chlorpheniramine on skin responses while also attenuating some sedative side effects caused by chlorpheniramine alone[2][3].
- Other names
- chlorpheniramine + ranitidinechlorpheniramine maleate + ranitidine hydrochloride
02
Targets
HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on chlorpheniramine + ranitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + ranitidine.